Title :

Graft-versus-Host Disease Prophylaxis with Post Transplant Cyclophosphamide in Chronic Myeloid Leukemia patients undergoing Allogeneic Hematopoietic Cell Transplant from either an Unrelated or Mismatched Related Donor: a comparative study from the Chr...

Author(s) :

Ortí, Guillermo [Auteur]
Vall d'Hebron Institute of Oncology [Barcelone] [VHIO]
Gras, Luuk [Auteur]
Universiteit Leiden = Leiden University
Koster, Linda [Auteur]
Leiden University Medical Center [LUMC]
Kulagin, Aleksander [Auteur]
Pavlov First Saint Petersburg State Medical University [St. Petersburg]
Byrne, Jenny [Auteur]
Nottingham University Hospitals NHS Trust [NUH]
Halaburda, Kazimierz [Auteur]
Warsaw University of Technology [Warsaw]
Blau, Igor Wolfgang [Auteur]
Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
Clark, Andrew [Auteur]
University of Glasgow
Kröger, Nicolaus [Auteur]
University Hospital Hamburg-Eppendorf
Griskevicius, Laimonas [Auteur]
Vilnius University [Vilnius]
Carlson, Kristina [Auteur]
Uppsala University Hospital
Collin, Matthew [Auteur]
Newcastle Upon Tyne Hospitals NHS Foundation Trust
Bloor, Adrian [Auteur]
The Christie NHS Foundation Trust [Manchester, Royaume-Uni]
Raiola, Anna Maria [Auteur]
Istituto di ricovero e cura a carattere scientifico Azienda Ospedaliera Universitaria "San Martino" [IRCCS AOU San Martino]
Blaise, Didier [Auteur]
Aix Marseille Université [AMU]
Aljurf, Mahmoud [Auteur]
King Faisal Specialist Hospital and Resarch Centre [Riyadh, Saudi Arabia] [KFSHRC]
López Corral, Lucia [Auteur]
Universidad de Salamanca
Sakellari, Ioanna [Auteur]
Aristotle University of Thessaloniki
Beguin, Yves [Auteur]
Centre Hospitalier Universitaire de Liège [CHU-Liège]
Wrobel, Tomasz [Auteur]
University of Wrocław [Poland] [UWr]
De Rosa, Luca [Auteur]
Ospedale San Camillo-Forlanini
De Lavallade, Hughes [Auteur]
NHS Foundation Trust [London]
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Mclornan, Donal P. [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Chalandon, Yves [Auteur]
Université de Genève = University of Geneva [UNIGE]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Journal title :

Transplantation and Cellular Therapy

Abbreviated title :

Transplant Cell Ther

Publication date :

2023-10-04

ISSN :

2666-6367

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) for chronic myeloid leukemia (CML) with post-transplantation cyclophosphamide (PTCy) using an unrelated donor (UD) or a mismatched related donor ...
Show more >Outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) for chronic myeloid leukemia (CML) with post-transplantation cyclophosphamide (PTCy) using an unrelated donor (UD) or a mismatched related donor (MMRD) remain unknown. We report a retrospective comparison of PTCy-based allo-HCT from a UD, non-PTCy allo-HCT from a UD, and PTCy allo-HCT from an MMRD. Inclusion criteria were adult patients with CML undergoing first allo-HCT between 2012 and 2019 from a UD with either PTCy or non-PTCy graft-versus-host disease (GVHD) prophylaxis or from an MMRD using PTCy. The primary endpoint was GVHD-free/relapse-free survival (GRFS). A total of 1341 patients were included (82% in the non-PTCy UD cohort). With a median follow-up of 34.9 months, the 3-year GRFS was 43% in the non-PTCy cohort, 37% in the PTCy-UD cohort, and 39% PTCy-MMRD cohort (P = .15). Multivariable analyses revealed no significant differences among the 3 cohorts in terms of overall survival (OS), progression-free survival, RI, and nonrelapse mortality. Factors independently associated with worse OS in the overall cohort were Karnofsky Performance Status <90 (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.41 to 2.45; P < .001), older age (HR, 1.24, 95% CI, 1.11 to 1.38; P < .001), and disease stage (compared to chronic phase [CP] 1): blast phase (HR, 2.25; 95% CI, 1.60 to 3.16; P < .001), accelerated phase (HR, 1.63; 95% CI, 1.05 to 2.54; P = .03), and CP >2 (HR, 1.58; 95% CI, 1.15 to 2.17; P = .005). These results suggest that allo-HCT in patients with CML using either a UD or an MMRD with PTCy-based GVHD prophylaxis are feasible transplantation, platforms and that the disease stage at allo-HCT remains a major prognostic factor, highlighting the importance of closely monitoring CML patients and proposing transplantation when indicated when still in CP1.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-02-06T22:26:21Z
2024-03-20T10:31:12Z
2024-03-20T12:47:40Z